News

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Healthline15h
FDA Accepts Novo Nordisk’s Application for Oral Wegovy: 5 Things to Know
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
The Economist8d
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...
Indianapolis Business Journal1d
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Money Morning1d
Eli Lilly (LLY): Should You Buy or Sell After Drug Price Order?
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
STAT1d
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
BioSpace3d
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...